Ainos highlights ‘continued expansion’ of Smell AI deployments

Ainos (AIMD) highlighted the continued expansion of its Smell AI deployments, powered by AI Nose, across semiconductor, robotics, and healthcare infrastructure, highlighted by recent third-party research published by VASRO. The company said, “The report underscores Smell AI’s progression from isolated sensing applications to scalable multi-domain AI perception platform and identifies 2026 as a key scale-up year as Ainos moves toward deployment and repeatable revenue generation. As part of this expansion, Ainos is initiating deployment of Smell AI within hospital infrastructure through collaboration with MacKay Memorial Hospital and Topco Scientific Co., Ltd. Initial applications focus on environmental monitoring and safety across power and electromechanical systems, HVAC infrastructure, chemical handling environments, and clinical laboratory settings, including MRI facilities. According to the report, these environments position Smell AI as an early perception layer for otherwise invisible environmental signals, including chemical exposure and airborne germs, supporting improved safety and operational resilience in hospital settings. The hospital deployment positions Smell AI to extend beyond its established semiconductor and industrial use cases into another high-standard operating environment, reinforcing its ability to scale across real-world infrastructure. The report also highlights Smell AI’s evolution toward broader platform adoption through AI Nose, which converts invisible scent signals into structured, machine-readable Smell ID data that can compound across deployments.”